{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:14:56Z","timestamp":1769598896781,"version":"3.49.0"},"reference-count":123,"publisher":"Portland Press Ltd.","issue":"6","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":1724,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,1]]},"abstract":"<jats:p>STS (soft tissue sarcomas) are rare malignant tumours deriving from cells of mesenchymal origin and represent only 1% of all malignant neoplasms. It has been extensively demonstrated that angiogenesis has an important role in cancer malignancy. Particularly, a lot of studies demonstrate the importance of angiogenesis in the development of carcinomas, whereas little is known about the role of angiogenesis in sarcomas and especially in STS. This review aims at summarizing the new discoveries about the nature and the importance of angiogenesis in STS and the new possible therapeutic strategies involved. Only a few studies concerning STS focus on tumour neovascularization and proangiogenic factors and look for a correlation with the patients prognosis\/survival. These studies demonstrate that intratumoural MVD (microvessels density) may not accurately represent the angiogenic capacity of STS. Nevertheless, this does not exclude the possibility that angiogenesis could be important in STS. The importance of neoangiogenesis in soft tissue tumours is confirmed by the arising number of publications comparing angiogenesis mediators with clinical features of patients with STS. The efficacy of anti-angiogenic therapies in other types\u00a0of cancer is well documented. The understanding of the involvement of the angiogenic process in STS, together with the necessity to improve the therapy for this often mortal condition, prompted the exploration of anti-tumour compounds targeting this pathway. In conclusion, this review emphasizes the importance to better understand the mechanisms of angiogenesis in STS in order to subsequently design-specific target therapies for this group of poorly responding tumours.<\/jats:p>","DOI":"10.1042\/bsr20140075","type":"journal-article","created":{"date-parts":[[2014,9,29]],"date-time":"2014-09-29T09:12:05Z","timestamp":1411981925000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets"],"prefix":"10.1042","volume":"34","author":[{"given":"Laura","family":"Rocchi","sequence":"first","affiliation":[{"name":"Unit\u00e0 Operativa di Anatomia e Istologia Patologica, Azienda Ospedaliero-Universitaria di Parma, Via Gramsci, 14, 43100-Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Caraffi","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa di Anatomia e Istologia Patologica, Azienda Ospedaliero-Universitaria di Parma, Via Gramsci, 14, 43100-Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Perris","sequence":"additional","affiliation":[{"name":"COMT\u2013Centro di Oncologia Medica e Traslazionale, Universit\u00e0 di Parma, Parco Area delle Scienze 11\/A 43100-Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenica","family":"Mangieri","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa di Anatomia e Istologia Patologica, Azienda Ospedaliero-Universitaria di Parma, Via Gramsci, 14, 43100-Parma, Italy"},{"name":"COMT\u2013Centro di Oncologia Medica e Traslazionale, Universit\u00e0 di Parma, Parco Area delle Scienze 11\/A 43100-Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2014,11,4]]},"reference":[{"key":"2021111618231317300_B1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3322\/canjclin.54.2.94","article-title":"Soft tissue sarcomas","volume":"54","author":"Cormier","year":"2004","journal-title":"CA Cancer J. Clin."},{"key":"2021111618231317300_B2","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nature04478","article-title":"Angiogenesis in life, disease and medicine","volume":"438","author":"Carmeliet","year":"2005","journal-title":"Nature"},{"key":"2021111618231317300_B3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000227427","article-title":"Angiogenesis in malignant fibrous histiocytoma","volume":"52","author":"Ohsawa","year":"1995","journal-title":"Oncology"},{"key":"2021111618231317300_B4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/BF02303764","article-title":"Neovascularity and clinical outcome in high-grade extremity soft tissue sarcomas","volume":"5","author":"Saenz","year":"1998","journal-title":"Ann. Surg. Oncol."},{"key":"2021111618231317300_B5","first-page":"959","article-title":"Angiogenesis does not correlate with prognosis or expression of vascular endothelial growth factor in synovial sarcomas","volume":"6","author":"Kawauchi","year":"1999","journal-title":"Oncol. Rep."},{"key":"2021111618231317300_B6","first-page":"3516","article-title":"Different patterns of angiogenesis in sarcomas and carcinomas","volume":"5","author":"Tomlinson","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"2021111618231317300_B7","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.ejso.2005.04.012","article-title":"Microvessel density does not predict outcome in high grade soft tissue sarcoma","volume":"31","author":"West","year":"2005","journal-title":"Eur. J. Surg. Oncol."},{"key":"2021111618231317300_B8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.critrevonc.2007.01.006","article-title":"Vascular endothelial growth factor (VEGF) signaling in tumor progression","volume":"62","author":"Roskoski","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2021111618231317300_B9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1472-6890-14-5","article-title":"The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk","volume":"14","author":"Kilvaer","year":"2014","journal-title":"BMC Clin. Pathol."},{"key":"2021111618231317300_B10","doi-asserted-by":"publisher","first-page":"5243","DOI":"10.1002\/cncr.24562","article-title":"Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma","volume":"115","author":"Abdeen","year":"2009","journal-title":"Cancer"},{"key":"2021111618231317300_B11","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1158\/1078-0432.CCR-08-2534","article-title":"A three-gene signature for outcome in soft tissue sarcoma","volume":"15","author":"Hoffmann","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"2021111618231317300_B12","first-page":"7163","article-title":"Fibroblast growth factors are required for efficient tumor angiogenesis","volume":"60","author":"Compagni","year":"2000","journal-title":"Cancer Res."},{"key":"2021111618231317300_B13","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1083\/jcb.141.7.1659","article-title":"Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis","volume":"141","author":"Seghezzi","year":"1998","journal-title":"J. Cell Biol."},{"key":"2021111618231317300_B14","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1152\/physrev.1999.79.4.1283","article-title":"Mechanism of action and in\u00a0vivo role of platelet-derived growth factor","volume":"79","author":"Heldin","year":"1999","journal-title":"Physiol. Rev."},{"key":"2021111618231317300_B15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1478-811X-11-97","article-title":"Targeting the PDGF signaling pathway in tumor treatment","volume":"11","author":"Heldin","year":"2013","journal-title":"Cell Commun. Signal."},{"key":"2021111618231317300_B16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/bjc.2012.328","article-title":"Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study","volume":"107","author":"Sleijfer","year":"2012","journal-title":"Br. J. Cancer"},{"key":"2021111618231317300_B17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1161\/01.ATV.0000105902.89459.09","article-title":"Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels","volume":"24","author":"Delafontaine","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021111618231317300_B18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.canlet.2012.08.018","article-title":"Angiopoietins in angiogenesis","volume":"328","author":"Fagiani","year":"2012","journal-title":"Cancer Lett."},{"key":"2021111618231317300_B19","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.hoc.2004.06.002","article-title":"Epidermal growth factor receptor in tumor angiogenesis","volume":"18","author":"Ellis","year":"2004","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"2021111618231317300_B20","first-page":"215","article-title":"HGF\/SF in angiogenesis","volume":"212","author":"Rosen","year":"1997","journal-title":"Ciba Found Symp."},{"key":"2021111618231317300_B21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/hupa.2000.8230","article-title":"Expression of hepatocyte growth factor (HGF)\/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma","volume":"31","author":"Oda","year":"2000","journal-title":"Hum. Pathol."},{"key":"2021111618231317300_B22","first-page":"119","article-title":"Hypoxia-inducible factor 1: regulation, involvement in carcinogenesis and target for anticancer therapy","volume":"92","author":"Clottes","year":"2005","journal-title":"Bull. Cancer"},{"key":"2021111618231317300_B23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.semcdb.2014.03.003","article-title":"From wavy hair to naked proteins: the role of transforming growth factor alpha in health and disease","volume":"28","author":"Singh","year":"2014","journal-title":"Semin. Cell Dev. Biol."},{"key":"2021111618231317300_B24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/jcp.21706","article-title":"Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis","volume":"219","author":"Ferrari","year":"2009","journal-title":"J. Cell Physiol."},{"key":"2021111618231317300_B25","doi-asserted-by":"publisher","first-page":"e17507","DOI":"10.1371\/journal.pone.0017507","article-title":"The prognostic impact of TGF-\u03b21, fascin, NF-\u03baB and PKC-\u03b6 expression in soft tissue sarcomas","volume":"6","author":"Valkov","year":"2011","journal-title":"PLoS ONE"},{"key":"2021111618231317300_B26","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/149185","article-title":"Chronic inflammation and cytokines in the tumor microenvironment","author":"Landskron","year":"2014","journal-title":"J. Immunol. Res."},{"key":"2021111618231317300_B27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fphys.2014.00114","article-title":"The role IL-1\u00a0in tumor-mediated angiogenesis","volume":"5","author":"Voronov","year":"2014","journal-title":"Front. Physiol."},{"key":"2021111618231317300_B28","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.4049\/jimmunol.170.6.3369","article-title":"IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis","volume":"170","author":"Li","year":"2003","journal-title":"J. Immunol."},{"key":"2021111618231317300_B29","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/ijc.10496","article-title":"Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis","volume":"100","author":"Rutkowski","year":"2002","journal-title":"Int. J. Cancer."},{"key":"2021111618231317300_B30","article-title":"Targeting angiogenesis for controlling neuroblastoma","author":"Roy Choudhury","year":"2011","journal-title":"J. Oncol."},{"key":"2021111618231317300_B31","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1111\/j.1538-7836.2006.01995.x","article-title":"Angiogenin: a review of the pathophysiology and potential clinical applications","volume":"4","author":"Tello-Montoliu","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"2021111618231317300_B32","doi-asserted-by":"publisher","first-page":"C987","DOI":"10.1152\/ajpcell.00406.2006","article-title":"Stroma-derived factor (SDF1\/CXCL12) and human tumor pathogenesis","volume":"292","author":"Kryczek","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2021111618231317300_B33","doi-asserted-by":"publisher","first-page":"a006627","DOI":"10.1101\/cshperspect.a006627","article-title":"Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2","volume":"2","author":"Lawler","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2021111618231317300_B34","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1200\/JCO.2008.17.4706","article-title":"Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510\u00a0in patients with advanced soft tissue sarcoma","volume":"26","author":"Baker","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"2021111618231317300_B35","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/jcb.20480","article-title":"Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated","volume":"96","author":"Wahl","year":"2005","journal-title":"J. Cell Biochem."},{"key":"2021111618231317300_B36","first-page":"273","article-title":"Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth","volume":"79","author":"O\u2019Reilly","year":"1997","journal-title":"EXS."},{"key":"2021111618231317300_B37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.bone.2013.07.035","article-title":"Effects of endostar combined multidrug chemotherapy in osteosarcoma","volume":"57","author":"Xu","year":"2013","journal-title":"Bone"},{"key":"2021111618231317300_B38","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/b111897","article-title":"Vasostatins. Vascular targets","volume":"482","author":"Helle","year":"2000","journal-title":"Adv. Exp. Med. Biol."},{"key":"2021111618231317300_B39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1756-8722-6-42","article-title":"Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology","volume":"6","author":"Pilatova","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"2021111618231317300_B40","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/00001721-200212000-00001","article-title":"Antithrombin: a new look at the actions of a serine protease inhibitor","volume":"13","author":"Roemisch","year":"2002","journal-title":"J. Blood Coagul. Fibrinolysis"},{"key":"2021111618231317300_B41","first-page":"111","article-title":"Tissue inhibitors of metalloproteinases: structure, regulation and biological functions","volume":"74","author":"Gomez","year":"1997","journal-title":"Eur. J. Cell Biol."},{"key":"2021111618231317300_B42","first-page":"155","article-title":"Correlation between matrix metalloproteinases-2 and tissue inhibitor of metalloproteinase-2 expression, metastatic potential and tumor angiogenesis in synovial sarcoma and its prognostic significance","volume":"35","author":"Sun","year":"2006","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"2021111618231317300_B43","first-page":"1035","article-title":"Tissue and serum loss of metalloproteinase inhibitors in high grade soft tissue sarcomas","volume":"18","author":"Benassi","year":"2003","journal-title":"Histol. Histopathol."},{"key":"2021111618231317300_B44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000012151","article-title":"Gelatinase and inhibitor expression in soft tissue sarcomas: lack of correlation with distant metastasis","volume":"59","author":"Maguire","year":"2000","journal-title":"Oncology"},{"key":"2021111618231317300_B45","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1517\/13543784.2013.793306","article-title":"Targeting angiopoietin-2 signaling in cancer therapy Expert Opin","volume":"22","author":"Eroglu","year":"2013","journal-title":"Investig. Drugs"},{"key":"2021111618231317300_B46","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.yexcr.2013.03.011","article-title":"Angiopoietin signaling in the vasculature","volume":"319","author":"Eklund","year":"2013","journal-title":"Exp. Cell Res."},{"key":"2021111618231317300_B47","first-page":"3591","article-title":"Expression of vascular endothelial growth factor and its receptor, KDR\/Flk-1, in soft tissue sarcomas","volume":"25","author":"Pakos","year":"2005","journal-title":"Anticancer Res."},{"key":"2021111618231317300_B48","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s10434-001-0260-9","article-title":"Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade","volume":"8","author":"Chao","year":"2001","journal-title":"Ann. Surg. Oncol."},{"key":"2021111618231317300_B49","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1054\/bjoc.2001.1837","article-title":"Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas","volume":"84","author":"Yudoh","year":"2001","journal-title":"Br. J. Cancer"},{"key":"2021111618231317300_B50","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/bjs.4398","article-title":"Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma","volume":"91","author":"Hayes","year":"2004","journal-title":"Br. J. Surg."},{"key":"2021111618231317300_B51","doi-asserted-by":"publisher","first-page":"e15368","DOI":"10.1371\/journal.pone.0015368","article-title":"Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis","volume":"5","author":"Kilvaer","year":"2010","journal-title":"PLoS ONE"},{"key":"2021111618231317300_B52","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature07083","article-title":"Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation","volume":"454","author":"Tammela","year":"2008","journal-title":"Nature"},{"key":"2021111618231317300_B53","first-page":"560","article-title":"Cell proliferation in human soft tissue tumors correlates with platelet-derived growth factor B chain expression: an immunohistochemical and in situ hybridization study","volume":"54","author":"Wang","year":"1994","journal-title":"Cancer Res."},{"key":"2021111618231317300_B54","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s004320050319","article-title":"Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma","volume":"125","author":"Graeven","year":"1999","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2021111618231317300_B55","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jss.2006.01.023","article-title":"Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression","volume":"135","author":"Yoon","year":"2006","journal-title":"J. Surg. Res."},{"key":"2021111618231317300_B56","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1479-5876-9-104","article-title":"Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients","volume":"9","author":"Kilvaer","year":"2011","journal-title":"J. Transl. Med."},{"key":"2021111618231317300_B57","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/(SICI)1097-0215(19960822)69:4&lt;268::AID-IJC5&gt;3.0.CO;2-V","article-title":"Urokinase-plasminogen- activator levels and prognosis in 69 soft-tissue sarcomas","volume":"69","author":"Choong","year":"1996","journal-title":"Int. J. Cancer"},{"key":"2021111618231317300_B58","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1023\/A:1008318614461","article-title":"Metalloproteinase expression and prognosis in soft tissue sarcomas","volume":"12","author":"Benassi","year":"2001","journal-title":"Ann. Oncol."},{"key":"2021111618231317300_B59","doi-asserted-by":"publisher","first-page":"17505","DOI":"10.1073\/pnas.0908026106","article-title":"Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature","volume":"106","author":"Hedlund","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2021111618231317300_B60","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.biocel.2010.11.018","article-title":"Chaotic neovascularization induced by aggressive fibrosarcoma cells overexpressing S-adenosylmethionine decarboxylase","volume":"43","author":"Paasinen-Sohns","year":"2011","journal-title":"Int. J. Biochem. Cell. Biol."},{"key":"2021111618231317300_B61","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.2353\/ajpath.2006.060223","article-title":"Tumor cell plasticity in uveal melanoma: microenvironment directed dampening of the invasive and metastatic genotype and phenotype accompanies the generation of vasculogenic mimicry patterns","volume":"169","author":"Folberg","year":"2006","journal-title":"Am. J. Pathol."},{"key":"2021111618231317300_B62","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.1158\/0008-5472.CAN-04-4552","article-title":"Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers","volume":"65","author":"Di Tomaso","year":"2005","journal-title":"Cancer Res."},{"key":"2021111618231317300_B63","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1634\/theoncologist.12-8-1007","article-title":"The biology behind mTOR inhibition in sarcoma","volume":"12","author":"Wan","year":"2007","journal-title":"Oncologist"},{"key":"2021111618231317300_B64","doi-asserted-by":"publisher","first-page":"e19103","DOI":"10.1371\/journal.pone.0019103","article-title":"Amplification of the angiogenic signal through the activation of the TSC\/mTOR\/HIF axis by the KSHV vGPCR in Kaposi's sarcoma","volume":"6","author":"Jham","year":"2011","journal-title":"PLoS ONE"},{"key":"2021111618231317300_B65","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/626094","article-title":"Targeted therapies in sarcomas: challenging the challenge","author":"Mart\u00edn Liberal","year":"2012","journal-title":"Sarcoma"},{"key":"2021111618231317300_B66","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.critrevonc.2014.02.001","article-title":"Anti-angiogenic therapy, a new player in the field of sarcoma treatment","volume":"91","author":"Versleijen-Jonkers","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2021111618231317300_B67","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/pbc.24547","article-title":"Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors","volume":"60","author":"Wagner","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"2021111618231317300_B68","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/annonc\/mdr299","article-title":"Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen","volume":"23","author":"Verschraegen","year":"2012","journal-title":"Ann. Oncol."},{"key":"2021111618231317300_B69","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.ijrobp.2010.07.024","article-title":"Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas","volume":"81","author":"Yoon","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2021111618231317300_B70","doi-asserted-by":"publisher","first-page":"7135","DOI":"10.1200\/JCO.2005.16.139","article-title":"Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas","volume":"23","author":"D\u2019Adamo","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"2021111618231317300_B71","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00280-014-2389-9","article-title":"A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFR\u03b1) monoclonal antibody, in patients with advanced solid tumors","volume":"73","author":"Chiorean","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2021111618231317300_B72","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1158\/1078-0432.CCR-12-0098","article-title":"A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer","volume":"18","author":"Rosen","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"2021111618231317300_B73","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/pbc.24605","article-title":"Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group","volume":"61","author":"Weigel","year":"2014","journal-title":"Pediatr. Blood Cancer."},{"key":"2021111618231317300_B74","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1016\/j.ejca.2013.06.010","article-title":"An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours","volume":"49","author":"Sch\u00f6ffski","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"2021111618231317300_B75","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1470-2045(13)70049-4","article-title":"Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial","volume":"14","author":"Schwartz","year":"2013","journal-title":"Lancet Oncol."},{"key":"2021111618231317300_B76","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1200\/JCO.2011.37.4355","article-title":"Phase I\/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group","volume":"30","author":"Malempati","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"2021111618231317300_B77","doi-asserted-by":"publisher","first-page":"6052","DOI":"10.1158\/1078-0432.CCR-10-2979","article-title":"Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer","volume":"17","author":"Naing","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"2021111618231317300_B78","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1470-2045(09)70354-7","article-title":"Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study","volume":"11","author":"Olmos","year":"2010","journal-title":"Lancet Oncol."},{"key":"2021111618231317300_B79","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1158\/1078-0432.CCR-10-2621","article-title":"Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors","volume":"17","author":"Quek","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"2021111618231317300_B80","doi-asserted-by":"publisher","first-page":"5800","DOI":"10.1200\/JCO.2009.23.6745","article-title":"Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1","volume":"27","author":"Tolcher","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"2021111618231317300_B81","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1158\/1078-0432.CCR-11-3369","article-title":"Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors","volume":"18","author":"Rosen","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"2021111618231317300_B82","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ejca.2011.12.008","article-title":"First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I\/II open-label and double-blind study","volume":"48","author":"Demetri","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"2021111618231317300_B83","first-page":"3056","article-title":"Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3","volume":"6","author":"Gutheil","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"2021111618231317300_B84","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1089\/108497801300189218","article-title":"A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer","volume":"16","author":"Posey","year":"2001","journal-title":"Cancer Biother. Radiopharm."},{"key":"2021111618231317300_B85","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10637-007-9077-0","article-title":"Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors","volume":"26","author":"Delbaldo","year":"2008","journal-title":"Invest. New Drugs"},{"key":"2021111618231317300_B86","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1200\/JCO.2008.20.9890","article-title":"Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas","volume":"27","author":"George","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"2021111618231317300_B87","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.ygyno.2009.09.011","article-title":"Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a gynecologic oncology group phase II study","volume":"115","author":"Hensley","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"2021111618231317300_B88","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1002\/ijc.25843","article-title":"Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma","volume":"129","author":"Mahmood","year":"2011","journal-title":"Int. J. Cancer"},{"key":"2021111618231317300_B89","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1158\/1078-0432.CCR-11-0237","article-title":"Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study","volume":"17","author":"Dubois","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"2021111618231317300_B90","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/annonc\/mds607","article-title":"Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy","volume":"24","author":"Santoro","year":"2013","journal-title":"Ann. Oncol."},{"key":"2021111618231317300_B91","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/cncr.26334","article-title":"Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas","volume":"118","author":"von Mehren","year":"2012","journal-title":"Cancer"},{"key":"2021111618231317300_B92","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10637-009-9367-9","article-title":"Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial","volume":"29","author":"Pacey","year":"2011","journal-title":"Invest. New Drugs"},{"key":"2021111618231317300_B93","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","article-title":"Phase II study of sorafenib in patients with metastatic or recurrent sarcomas","volume":"27","author":"Maki","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"2021111618231317300_B94","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1200\/JCO.2012.47.0914","article-title":"Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report","volume":"31","author":"Glade Bender","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"2021111618231317300_B95","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/bjc.2012.328","article-title":"Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study","volume":"107","author":"Sleijfer","year":"2012","journal-title":"Br. J. Cancer"},{"key":"2021111618231317300_B96","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"2021111618231317300_B97","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","article-title":"Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043)","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"2021111618231317300_B98","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/bjc.2013.380","article-title":"A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004\/NCI 8503) Br","volume":"109","author":"Sahebjam","year":"2013","journal-title":"J. Cancer"},{"key":"2021111618231317300_B99","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1200\/JCO.2012.47.4288","article-title":"Cediranib for metastatic alveolar soft part sarcoma","volume":"31","author":"Kummar","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"2021111618231317300_B100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.48.7462","article-title":"Extended progression-free survival in two patients with alveolar soft part sarcoma exposed to tivantinib","author":"Goldberg","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"2021111618231317300_B101","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1158\/1078-0432.CCR-04-0157","article-title":"Phase II study of the antiangiogenic agent SU5416\u00a0in patients with advanced soft tissue sarcomas","volume":"10","author":"Heymach","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"2021111618231317300_B102","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1634\/theoncologist.2008-0065","article-title":"A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens","volume":"13","author":"Ray-Coquard","year":"2008","journal-title":"Oncologist"},{"key":"2021111618231317300_B103","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1200\/JCO.2005.11.429","article-title":"Children's Oncology Group. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a children's oncology group study","volume":"23","author":"Daw","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"2021111618231317300_B104","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/ijc.28083","article-title":"A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma","volume":"133","author":"Thornton","year":"2013","journal-title":"Int. J. Cancer"},{"key":"2021111618231317300_B105","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1002\/cncr.25928","article-title":"A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C)","volume":"117","author":"Okuno","year":"2011","journal-title":"Cancer"},{"key":"2021111618231317300_B106","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.ejca.2012.03.022","article-title":"Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma","volume":"48","author":"Schuetze","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"2021111618231317300_B107","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1200\/JCO.2011.35.6329","article-title":"Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas","volume":"30","author":"Chawla","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"2021111618231317300_B108","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/annonc\/mds602","article-title":"Phase I\/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma","volume":"24","author":"Mita","year":"2013","journal-title":"Ann. Oncol."},{"key":"2021111618231317300_B109","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1200\/JCO.2012.45.5766","article-title":"Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy","volume":"31","author":"Demetri","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"2021111618231317300_B110","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/cam4.65","article-title":"A phase I study of ABT-510 plus bevacizumab in advanced solid tumors","volume":"2","author":"Uronis","year":"2013","journal-title":"Cancer Med."},{"key":"2021111618231317300_B111","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1200\/JCO.2008.17.4706","article-title":"Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510\u00a0in patients with advanced soft tissue sarcoma","volume":"26","author":"Baker","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"2021111618231317300_B112","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/annonc\/mdl102","article-title":"A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors","volume":"17","author":"Gietema","year":"2006","journal-title":"Ann. Oncol."},{"key":"2021111618231317300_B113","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ygyno.2011.11.042","article-title":"A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California cancer Phase II Consortia","volume":"125","author":"Mackay","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"2021111618231317300_B114","doi-asserted-by":"publisher","first-page":"5081","DOI":"10.1158\/1078-0432.CCR-12-0078","article-title":"A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report","volume":"18","author":"Glade Bender","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"2021111618231317300_B115","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/jso.21724","article-title":"Tumor vascularization and histopathological regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-\u03b1 and Melphalan","volume":"103","author":"Grabellus","year":"2011","journal-title":"J. Surg. Oncol."},{"key":"2021111618231317300_B116","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/127170","article-title":"Angiogenesis and its therapeutic opportunities","author":"Yoo","year":"2013","journal-title":"Mediators Inflamm."},{"key":"2021111618231317300_B117","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cyto.2011.01.005","article-title":"Blockade of the Ras\/MEK\/ERK and Ras\/PI3K\/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-\u03b2 as angiogenic factors in mouse osteosarcoma","volume":"54","author":"Tsubaki","year":"2011","journal-title":"Cytokine"},{"key":"2021111618231317300_B118","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2174\/157488411796151174","article-title":"Tissue protective and anti-fibrotic actions of suramin: new uses of an old drug","volume":"6","author":"Liu","year":"2011","journal-title":"Curr. Clin. Pharmacol."},{"key":"2021111618231317300_B119","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.peptides.2011.08.010","article-title":"An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in\u00a0vivo","volume":"32","author":"Seo","year":"2011","journal-title":"Peptides"},{"key":"2021111618231317300_B120","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S0748-7983(97)93077-8","article-title":"Phase I\/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites","volume":"23","author":"Parsons","year":"1997","journal-title":"Eur. J. Surg. Oncol."},{"key":"2021111618231317300_B121","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.ajpath.2011.06.021","article-title":"CSF1 expression in nogynecolagical leiomyosarcoma is associated with increased tumor angiogenesis","volume":"179","author":"Espinosa","year":"2011","journal-title":"Am. J. Pathol."},{"key":"2021111618231317300_B122","first-page":"3391","article-title":"The effect of bevacizumab on tumour growth of malignant fibrous histiocytoma in an animal model","volume":"30","author":"Okada","year":"2010","journal-title":"Anticancer Res."},{"key":"2021111618231317300_B123","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.ijrobp.2009.02.052","article-title":"Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma","volume":"74","author":"Yoon","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20140075\/476854\/bsr034e147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20140075\/476854\/bsr034e147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T18:54:30Z","timestamp":1637088870000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/34\/6\/e00147\/56266\/The-angiogenic-asset-of-soft-tissue-sarcomas-a-new"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,4]]},"references-count":123,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12,1]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20140075","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,4]]},"article-number":"e00147"}}